Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Zenas Biopharma Inc (ZBIO)

Zenas Biopharma Inc (ZBIO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,082,169
  • Shares Outstanding, K 53,679
  • Annual Sales, $ 5,000 K
  • Annual Income, $ -156,990 K
  • EBIT $ -194 M
  • EBITDA $ -194 M
  • 60-Month Beta -1.45
  • Price/Sales 56.37
  • Price/Cash Flow N/A
  • Price/Book 4.27

Options Overview Details

View History
  • Implied Volatility 131.39% (+6.43%)
  • Historical Volatility 245.03%
  • IV Percentile 77%
  • IV Rank 48.47%
  • IV High 189.19% on 01/02/26
  • IV Low 77.01% on 11/12/25
  • Expected Move (DTE 34) 5.41 (26.86%)
  • Put/Call Vol Ratio 0.22
  • Today's Volume 167
  • Volume Avg (30-Day) 906
  • Put/Call OI Ratio 0.45
  • Today's Open Interest 8,544
  • Open Int (30-Day) 5,522
  • Expected Range 14.75 to 25.57

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 9 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.22
  • Number of Estimates 3
  • High Estimate -0.32
  • Low Estimate -2.06
  • Prior Year N/A
  • Growth Rate Est. (year over year) -100.12%

Price Performance

See More
Period Period Low Period High Performance
1-Month
13.50 +49.33%
on 01/05/26
44.60 -54.80%
on 12/24/25
-16.73 (-45.35%)
since 12/16/25
3-Month
13.50 +49.33%
on 01/05/26
44.60 -54.80%
on 12/24/25
-4.05 (-16.73%)
since 10/16/25
52-Week
5.83 +245.80%
on 01/28/25
44.60 -54.80%
on 12/24/25
+12.38 (+159.13%)
since 01/16/25

Most Recent Stories

More News
Zenas BioPharma Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Jan. 16, 2026 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader...

ZBIO : 20.16 (+1.15%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

NEW YORK , Jan. 15, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised...

ZBIO : 20.16 (+1.15%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised...

ZBIO : 20.16 (+1.15%)
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Zenas BioPharma, Inc. - ZBIO

NEW YORK , Jan. 8, 2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Zenas BioPharma, Inc. ("Zenas" or the "Company") (NASDAQ: ZBIO). Such investors are advised...

ZBIO : 20.16 (+1.15%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)

NEW YORK , Jan. 5, 2026 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders.  The investigation...

ZBIO : 20.16 (+1.15%)
Zenas BioPharma Announces Positive Results from Phase 3 INDIGO Registrational Trial of Obexelimab in Immunoglobulin G4-Related Disease (IgG4-RD)

- Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD flare - - Obexelimab also met and demonstrated statistically...

ZBIO : 20.16 (+1.15%)
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

WALTHAM, Mass., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Zenas BioPharma, Inc. (“Zenas” or the “Company”) (Nasdaq: ZBIO), a clinical-stage global biopharmaceutical company committed to being a leader...

ZBIO : 20.16 (+1.15%)
Zenas BioPharma’s Partner, InnoCare Pharma, Announces Achievement of Primary Endpoint in Phase 2b Study of Orelabrutinib, a BTK Inhibitor, for Systemic Lupus Erythematosus

- Orelabrutinib is the first BTK inhibitor to demonstrate significant clinical activity in a Phase 2 clinical trial for SLE - - Zenas acquired the exclusive right to develop, manufacture and commercialize...

ZBIO : 20.16 (+1.15%)
SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Zenas BioPharma, Inc. (NASDAQ: ZBIO)

NEW YORK , Nov. 20, 2025 /PRNewswire/ -- Purcell & Lefkowitz LLP announces that it is investigating Zenas BioPharma, Inc. (NASDAQ: ZBIO) on behalf of the company's shareholders. The investigation...

ZBIO : 20.16 (+1.15%)
Zenas BioPharma Reports Third Quarter 2025 Financial Results and Provides Corporate Update

- Obexelimab Phase 3 INDIGO trial topline results in Immunoglobulin G4-Related Disease (IgG4-RD) expected around year-end 2025 - - Reported highly positive 12-week primary endpoint results from Phase...

ZBIO : 20.16 (+1.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakening short term outlook on maintaining the current direction.

See More Share

Business Summary

Zenas BioPharma Inc. is a clinical-stage global biopharmaceutical company. It involved in the development and commercialization of transformative immunology-based therapies for patients in need. The company's lead product candidate includes obexelimab and Fc'RIIb. Zenas BioPharma Inc. is based in WALTHAM,...

See More

Key Turning Points

3rd Resistance Point 22.20
2nd Resistance Point 21.65
1st Resistance Point 20.90
Last Price 20.16
1st Support Level 19.60
2nd Support Level 19.05
3rd Support Level 18.31

See More

52-Week High 44.60
Fibonacci 61.8% 29.79
Fibonacci 50% 25.22
Fibonacci 38.2% 20.64
Last Price 20.16
52-Week Low 5.83

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar